MPO and bacterial vaginosis: While no conclusion can be drawn by this study on therapeutic potential, Jang et al. adapted the protocol in a BV animal study and noticed that both oral and intravaginal administration of Respecta® attenuated G. vaginalis-induced BV with decreased epithelial cell disruption and myeloperoxidase activity [292,293].